Sartorius Stedim Biotech's EBIT per Share for the
three
months ended in Mar. 2026 was €1.71.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €5.12.
During the past 12 months, the average EBIT per Share Growth Rate of Sartorius Stedim Biotech was 26.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -21.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -8.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sartorius Stedim Biotech's EBIT per Share or its related term are showing as below:
CHIX:DIMp'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.6 Med: 19.45 Max: 45.4
Current: -21.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sartorius Stedim Biotech was 45.40% per year. The lowest was -46.60% per year. And the median was 19.45% per year.
CHIX:DIMp's 3-Year EBIT Growth Rate is ranked worse than 84.93% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs CHIX:DIMp: -21.50
Sartorius Stedim Biotech (CHIX:DIMp) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sartorius Stedim Biotech EBIT per Share Related Terms
Sartorius Stedim Biotech EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a EBIT per Share of €5.12 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #586 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 84.9%.
Is Sartorius Stedim Biotech's EBIT per Share too high?
Sartorius Stedim Biotech's current EBIT per Share is €5.12. Based on the distribution chart, Sartorius Stedim Biotech ranks #586 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #586 out of 690 companies for EBIT per Share. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current EBIT per Share is €5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.60, compared to a current price of €180.90 — trading 12.9% below its estimated fair value. The current EBIT per Share is €5.12. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current EBIT per Share is €5.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €180.90 is trading 12.9% below its estimated GF Value™ of €207.60.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
EBIT per Share: €5.12
GF Value™: €207.60 vs. price of €180.90 (12.9% below fair value)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
